ASA: Intra-Arterial Tenecteplase Beneficial for Large Vessel Occlusion
By Elana Gotkine HealthDay Reporter
TUESDAY, Feb. 18, 2025 -- For patients with large vessel occlusion presenting between 4.5 and 24 hours, intra-arterial tenecteplase after successful thrombectomy results in improved likelihood of excellent outcome (modified Rankin scale score 0 to 1), according to a study presented at the annual American Stroke Association International Stroke Conference, held from Feb. 5 to 7 in Los Angeles.
Xiaochuan Huo, M.D., Ph.D., from Beijing Anzhen Hospital, and colleagues conducted a multicenter, prospective, randomized trial involving patients with acute anterior circulation large vessel occlusion treated between 4.5 and 24 hours from the time last known to be well. After successful endovascular recanalization, patients were randomly assigned to receive intra-arterial tenecteplase or standard medical management (127 and 129 participants, respectively).
The researchers found that the percentage of patients with a modified Rankin scale score of 0 or 1 at 90 days was higher with intra-arterial tenecteplase versus standard medical treatment after endovascular therapy (40.5 versus 26.4 percent; relative rate, 1.44; 95 percent confidence interval, 1.06 to 1.95). Mortality at 90 days did not differ significantly between the groups and was 21.4 and 21.7 percent with intra-arterial tenecteplase and standard medical treatment, respectively. There was no significant difference seen in the incidence of symptomatic intracranial hemorrhage within 48 hours after treatment (5.6 and 6.2 percent with intra-arterial tenecteplase and standard medical treatment, respectively).
"Intra-arterial tenecteplase after successful thrombectomy could improve the percentage of people with an excellent outcome," Huo said in a statement. "It could also improve the rate of large vessel occlusion stroke survivors who can return to society and live independently."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Use of Vaginal Estradiol Tablets Not Linked to Recurrent Stroke
THURSDAY, Aug. 21, 2025 -- For women with a history of ischemic stroke, use of vaginal estradiol tablets is not associated with an increased rate of recurrent stroke, according to...
Seniors With Certain Cardiovascular Diseases Saw Life's Essential 8 Scores Decline 2013 to 2018
WEDNESDAY, Aug. 20, 2025 -- From 2013 to 2018, older adults with heart failure, stroke, and hypertension experienced significant declines in Life's Essential 8 (LE8) scores...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.